Clinical Trials Logo
  1. Home
  2. Diabetes Mellitus, Type 2
  3. NCT02036372

Perioperative Insulin, GIK or GLP-1 Treatment in Diabetes Mellitus — PILGRIM  

Diabetes Mellitus Type II Clinical Trial

Official title:
PILGRIM - Perioperative Insulin, GIK or GLP-1 Treatment in Diabetes Mellitus Type II

Clinical Trial Summary

The incidence of diabetes mellitus type II is increasing. More and more patients who need surgery have diabetes mellitus type II. Despite an enormous amount of glucose lowering protocols and the proven negative effects of hyperglycaemia. There is no evidence for the optimal glucose lowering protocol. This study investigates the optimal intraoperative treatment algorithm to lower glucose in patients with diabetes mellitus type 2 undergoing non-cardiac surgery, comparing intraoperative glucose-insulin-potassium infusion (GIK), insulin bolus regimen (BR) and GLP-1 (liraglutide, LG) treatment.

Clinical Trial Description

Diabetes mellitus is associated with poor outcome after surgery. The prevalence of diabetes in hospitalised patients is up to 40%, meaning that the anaesthesiologist will encounter a diabetes patient in the operating room on a daily basis. Multiple protocols for perioperative glucose regulation have been developed, ranging from intravenous glucose-insulin-potassium infusion to subcutaneous bolus regimens. Despite this abundance of published glucose lowering protocols and the proven negative effects of intraoperative hyperglycaemia in diabetes, there is no evidence regarding the optimal intraoperative glucose lowering treatment. Recently, incretins have been introduced to lower blood glucose. The main hormone of the incretin system is glucagon-like peptide-1 (GLP-1). GLP-1 increases insulin and decreases glucagon secretion in a glucose-dependent manner, resulting in low incidence of hypoglycaemia. This study investigates for the first time the optimal intraoperative treatment algorithm to lower glucose in patients with diabetes mellitus undergoing non-cardiac surgery. Objective: This study investigates the optimal intraoperative treatment algorithm to lower glucose in patients with diabetes mellitus type 2 undergoing non-cardiac surgery, comparing intraoperative glucose-insulin-potassium infusion (GIK), insulin bolus regimen (BR) and GLP-1 (liraglutide, LG) treatment. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02036372
Study type Interventional
Source Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Contact
Status Completed
Phase N/A
Start date January 2014
Completion date January 2017
View Details
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT02261545 - The Effect of n-3 Fatty Acid Supplementation on Serum Levels, and Gene Expression of type2 Diabetes Patient Phase 4
Completed NCT02028091 - Diabetes Mellitus - A Diagnosis Trial by Means of Non Invasive Measurements N/A
Completed NCT01684813 - VERifynow in DIabetes Non-responsiveness: a Study on Switching From Clopidogrel to Prasugrel Phase 4
Completed NCT01252524 - Effect of Calcium Polycarbophil on Type II Diabetes Mellitus Control: a Randomized Double-blind Study N/A
Recruiting NCT01311401 - Predictors of Future Type 2 Diabetes Mellitus in Circassians Minority in Israel N/A
Completed NCT00563225 - 20 Week Bridging Study in Type II DM Phase 3
Recruiting NCT01565096 - Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy Phase 4
Completed NCT00151697 - LANN-study: Lantus, Amaryl, Novorapid, Novomix Study Phase 3
Withdrawn NCT01453751 - Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered in Patients With Type II Diabetes N/A
Not yet recruiting NCT01775059 - Collection of Performance Data From the Integrated Sensor and Infusion Set. TRIAL 4 N/A
Completed NCT01281098 - Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen® (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation and PRP (Monotherapy) in the Treatment With High Risk PDR. Phase 2
Completed NCT01669473 - A Primary Care, EHR- Based Strategy to Promote Safe and Appropriate Drug Use N/A
Completed NCT03258840 - EPA Supplementation on Vascular Inflammation, and Gene Expression of PON2 in Patients With Type II Diabetes Mellitus N/A
Active, not recruiting NCT01386801 - Multicenter Research Study to Build a Repository to Study Chronic Diseases in Indiana N/A
Completed NCT02144948 - Investigation of the Effect of E.-Coli-Nissle as Supporting Therapy to Standard Care of Diabetes Mellitus Type II Phase 3